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Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza
and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza sur-
veillance system, we performed amulticenter, prospective cohort study of patients visiting emergency rooms with influenza-like
illness (ILI) during the influenza epidemic period in 2013 to 2014. Patients aged>19 years were enrolled, and clinical data were
collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in pre-
venting pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among
2,217 patients with available vaccination records, 31.9% (707 patients) and 9.7% (216 patients) had received influenza and pneu-
mococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4% had received the
23-valent polysaccharide vaccine (PPV23). The adjusted rates of effectiveness of the influenza vaccine for preventing pneumonia
development and hospitalization were 64.0% (95% confidence interval [CI] 29% to 81%) and 35.0% (95%CI 12% to 52%),
respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza
rather than PPV23 vaccinationmay reduce pneumonia development and hospitalization in patients with preceding ILI.
Influenza epidemics are responsible for approximately 20,000 to40,000 deaths and 114,000 hospitalizations annually (1, 2).
Community-acquired pneumonia (CAP) is the most common
and serious complication after influenza infection. The incidence
of influenza-related pneumonia has been reported to range from
0.1% to10%, depending on the level of epidemic and predom-
inant subtypes (3–5). Among diverse bacterial pneumonias,
pneumococcal pneumonia is especially common following influ-
enza infections (6). Influenza infections may lead to overexpres-
sion of pneumococcal binding receptors, impaired alveolar mac-
rophage phagocytosis, and neutrophil dysfunction, leading to
increased host susceptibility to pneumococcal infection (7).
Vaccination has been considered themost effectivemeasure to
prevent both influenza and pneumococcal pneumonia. In the Re-
public of Korea (ROK), the influenza vaccine coverage rate was an
estimated 80% in elderly individuals, and pneumococcal vaccina-
tion with the 23-valent pneumococcal polysaccharide vaccine
(PPV23) was adopted as the national immunization program for
elderly individuals (65 years of age) in May 2013 (8, 9). This
study evaluated the effectiveness of influenza and pneumococcal
vaccination alone or in combination to prevent pneumonia and
hospitalization following influenza-like illness (ILI).
MATERIALS AND METHODS
Study design. In the ROK, a multicenter prospective cohort study was
performed in 10 hospitals that had participated in a hospital-based influ-
enza surveillance system (Hospital-Based Influenza Morbidity and Mor-
tality [HIMM] system) since 2011 (10). During the 2013-2014 influenza
season (1 November 2013 to 30 April 2014), emergency room (ER)-based
surveillance was conducted by using ILI criteria; patients aged19 years
were enrolled. Clinical data and respiratory specimenswere collected pro-
spectively based on a standard protocol (10). A rapid influenza detection
test was performed at the bedside, and nasal/throat swab specimens were
transported to the central HIMM laboratory for multiplex respiratory
viral PCR testing. Patient clinical data were obtained by using a structured
case report form, which included demographics, underlying diseases, in-
fluenza/pneumococcal vaccination, and 30-day case fatalities. The study
design was approved by the ethics committee of each participating hospi-
tal, and written informed consent was obtained from all enrolled subjects.
Definition. ILI was defined as sudden onset of fever (38°C) accom-
panied by one or more respiratory symptoms, including cough, sore
throat, or nasal symptoms (10). Clinical, radiological, and microbiologi-
cal findings of all enrolled cases were evaluated to determine if patients
fulfilled the following clinical and radiological CAP criteria: (i) acute pul-
monary infiltrate consistent with pneumonia evident on chest radio-
graphs within 48 h after admission, (ii) confirmatory findings on clinical
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examination, and (iii) acquisition of infection outside the hospital setting
(11). Patients with health care-associated pneumonia or hospital-ac-
quired pneumonia were excluded (12).
Statistical analysis. Statistical analyses were performed by using SPSS
version 15.0 (SPSS Inc., Chicago, IL, USA). Significant differences in vari-
able distributions between groups were estimated by using the chi-square
or Fisher exact test for categorical variables and the Student t test for
quantitative variables. Quantitative data were expressed as means stan-
dard deviations. A bilateral P value of 0.05 was considered statistically
significant. Logistic regression was used to estimate the odds ratio for
pneumonia development and hospitalization in vaccinated versus unvac-
cinated subjects. Vaccine effectiveness (VE) was calculated as follows:
[100 (1 the odds ratio for pneumonia development or hospitalization
in vaccinated versus nonvaccinated persons)]. Logistic regression models
were adjusted for age, body mass index (BMI), and the presence of high-
risk medical conditions.
RESULTS
During the 2013-2014 ROK influenza season, 2,262 patients with
ILI were enrolled in the HIMM surveillance system, and vaccina-
tion records were available for 2,217 (98.0%). Among these 2,217
patients, 988 (44.6%) were laboratory confirmed as having influ-
enza, 70 (3.2%) had ILI accompanied by pneumonia, and 329
(14.8%) were hospitalized (Fig. 1). Twenty-two (1.0%) pa-
tients were admitted to the intensive care unit (ICU), and 13
(0.6%) patients died. Overall, 31.9% (707 patients) and 9.7%
(216 patients) had received influenza and pneumococcal vac-
cines, respectively. A total of 193 patients (8.7%) had previ-
ously received both the influenza and the pneumococcal vac-
cine. Among patients who had been administered a
pneumococcal vaccine, 94.4% (204 of 216 patients) had re-
ceived the PPV23. Both influenza and pneumococcal vaccina-
tion rates were significantly higher in elderly individuals (aged
65 years) than in young adults (Fig. 2).
The demographic and clinical characteristics of patients with
ILI are compared with respect to accompanying pneumonia in
Table 1. Patients with pneumonia were much older than those
without pneumonia (P 0.01); 72.9% of patients with pneumo-
nia were 65 years or older. Underlyingmedical diseases weremore
common in patients with pneumonia than in those without dia-
betes mellitus, chronic heart diseases, chronic lung diseases,
chronic renal diseases, and cerebrovascular diseases (P  0.01).
Patients with pneumonia were more likely to be admitted to the
ICU; they also died more often. Univariate analysis showed no
difference in influenza vaccination rates between both groups. In
contrast to what we expected, the pneumococcal vaccination rate
was higher in cases with pneumonia.
After adjustment for age, body mass index (BMI), current
smoking status, and the presence of chronic medical conditions,
the overall effectiveness of the influenza vaccine against pneumo-
nia development and hospitalization was 64% (95% confidence
interval [CI] 29% to 81%) and 35.0% (95%CI 12% to 52%),
respectively (Tables 2 and 3). Pneumococcal vaccination did not
reduce the development of pneumonia (odds ratio, 1.48; 95% CI,
FIG 1 Flowchart of cohort-enrolled subjects.
FIG 2 Age-stratified influenza and pneumococcus vaccine coverage rates.
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0.68 to 3.20) or hospitalization (odds ratio, 1.01; 95% CI, 0.68 to
1.52). Old age and chronic lung and renal diseases were indepen-
dent risk factors for pneumonia development and hospitalization.
Although insignificant for pneumonia development, multivariate
analysis showed chronic heart diseases to be an independent risk
factor for hospitalization.
Analysis of age-stratified VE showed the influenza vaccine to
be effective in preventing pneumonia (59.6%) and hospitalization
(54.9%) in elderly individuals (65 years of age) (Table 4; Fig. 3).
In comparison, pneumococcal vaccination was not effective.
Combined influenza and pneumococcal vaccination did not show
a synergistic effect for prevention of pneumonia (VE  20.7%;
95%CI70.8% to 63.2%) or hospitalization (VE 9.0%; 95%
CI  41.9% to 41.6%) (Fig. 3). In young adults aged 18 to 64
years, low vaccine coverage rates as well as low pneumonia and
hospitalization case numbers impeded VE estimation.
DISCUSSION
In this study, we evaluated the effectiveness of influenza and pneu-
mococcal vaccines for prevention of pneumonia and hospitaliza-
tion based on a large prospective cohort of patients with ILI. In-
fluenza vaccination reduced the risk of pneumonia development
and hospitalization in patients with ILI who visited the ER. In
comparison, pneumococcal vaccination did not show significant
preventive effectiveness.
Preceding influenza infection has been suggested to enhance
susceptibility to pneumococcal pneumonia as well as transmis-
sion between close contacts (6, 7). Increased susceptibility is re-
TABLE 1 Demographic and clinical characteristics with respect to pneumonia development
Characteristica Cases with pneumonia (n 70) Cases without pneumonia (n 2,147) P value
Age (yr; median SD) 70.1 15.2 47.2 19.4 0.01
Male sex, no. (%) 35 (50.0) 923 (43.0) 0.24
Body mass index (kg/m2) 22.4 4.1 23.1 3.7 0.13
Lab-confirmed influenza, no. (%) 68 (97.1) 920 (42.9) 0.01
Type A 41 631
Type B 22 258
Undetermined 0 31
Current smoking, no. (%) 9 (12.9) 342 (15.9) 0.62
Underlying diseases, no. (%)
Diabetes mellitus 16 (22.9) 238 (11.1) 0.01
Chronic heart diseases 11 (15.7) 122 (5.7) 0.01
Chronic lung diseases 12 (17.1) 50 (2.3) 0.01
Chronic renal diseases 7 (10.0) 56 (2.6) 0.01
Chronic liver diseases 2 (2.9) 39 (1.8) 0.53
Malignancies 7 (10.0) 142 (6.6) 0.23
HIV infection 1 (1.4) 6 (0.3) 0.09
Immunosuppressant use 2 (2.9) 36 (1.7) 0.34
HIV infection 1 (1.4) 6 (0.3) 0.09
Cerebrovascular diseases 9 (12.9) 78 (3.6) 0.01
Influenza vaccination, no. (%) 20 (28.6) 687 (32.0) 0.55
Pneumococcal vaccination, no. (%) 14 (20.0) 202 (9.4) 0.01
Admission, no. (%) 69 (98.6) 260 (12.1) 0.01
ICU admission, no. (%) 11 (15.7) 11 (0.5) 0.01
Mortality, no. (%) 9 (12.9) 4 (0.2) 0.01
a HIV, human immunodeficiency virus; ICU, intensive care unit.
TABLE 2 Multivariate logistic regression analysis of pneumonia risk
factors
Variable Odds ratio (95% CI) P value
Age (yr) 1.07 (1.05-1.09) 0.01
Body mass index 0.96 (0.89–1.03) 0.28
Current smoking 1.11 (0.52–2.36) 0.79
Diabetes mellitus 0.90 (0.45–1.78) 0.76
Chronic heart diseases 1.14 (0.54–2.43) 0.73
Chronic lung diseases 4.16 (1.98–8.75) 0.01
Chronic renal diseases 2.96 (1.12—7.87) 0.03
Cerebrovascular diseases 1.61 (0.70–3.69) 0.27
Influenza vaccination 0.36 (0.19–0.71) 0.01
Pneumococcal vaccination 1.48 (0.68–3.20) 0.33
TABLE 3 Multivariate logistic regression analysis of hospitalization risk
factors
Variable Odds ratio (95% CI) P value
Age 1.04 (1.03–1.05) 0.01
Body mass index 1.01 (0.97–1.04) 0.78
Current smoking 0.83 (0.57–1.22) 0.34
Diabetes mellitus 0.72 (0.50–1.04) 0.08
Chronic heart diseases 2.16 (1.44–3.24) 0.01
Chronic lung diseases 2.84 (1.64–4.94) 0.01
Chronic renal diseases 1.96 (1.06—3.60) 0.03
Cerebrovascular diseases 1.27 (0.77–2.11) 0.36
Influenza vaccination 0.65 (0.48–0.88) 0.01
Pneumococcal vaccination 1.01 (0.68–1.52) 0.95
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lated to the paradoxical suppression of the host immune system
and enhanced bacterial adherence to the respiratory epithelium.
As in previous reports, elderly people and patients with chronic
lung diseases were at the greatest risk for postinfluenza pneumo-
nia in this study (6, 13). In the ROK, immunization of elderly
individuals (aged65 years) with the PPV23 has been included in
the national immunization program (NIP) since May 2013, and
overall vaccine coverage rates were estimated to reach about 40%
by the end of 2013 (9). It is important to evaluate the effectiveness
of the pneumococcalNIP for elderly individuals in order to reduce
influenza- and pneumonia-related morbidity and mortality.
Recently, the Spanish influenza surveillance system reported
low VE in seasons with predominant circulation of influenza
A/H3N2 (14). Similarly, in the ROK, circulation of influenza
A/H3N2 was dominant in the past 3 years, with reportedly low
influenza VE (15, 16). Of note, this study showed that influenza
vaccination would be beneficial for elderly individuals and those
with comorbidities despite statistically insignificant influenza VE.
A previous retrospective study found influenza vaccination to be
associated with a 56%-reduced risk of hospitalization due to acute
exacerbation of cardiopulmonary disease despite suboptimal VE
(17). Although the influenza vaccine showed limited ability to
prevent influenza infection, it might have affected illness severity.
Influenza virus hemagglutinin (HA) is active early in respiratory
tract infections; therefore, it has been the main target of current
influenza vaccines. Influenza VE might decrease in proportion to
the degree that circulating viral HA differs from the HA of the
vaccine strain. We can hypothesize three mechanisms for the un-
expected protective effectiveness against pneumonia and hospi-
talization. First, even low inhibitory activity against variant HA
might prevent severe influenza infection and its complications.
Second, the effective antineuraminidase (anti-NA) activity of the
influenza vaccine might prevent pneumonia development and
hospitalization irrespective of infection itself. Although NA does
not have a significant role in initial infection, it might play an
important role in viral spread within the host and contribute to
development of pneumonia and other influenza-related compli-
cations. However, there is no serological data to support the pres-
ent explanation. Finally, vaccine-induced T-cell immunity against
influenza virus might be a factor in preventing influenza-related
complications also.
Unlike the influenza vaccine, the pneumococcal vaccine was
not effective in preventing pneumonia and hospitalization after
influenza infection. Pneumococcus is well known as themost com-
mon causative pathogen of secondary bacterial pneumonia after
influenza infection (6). Theoretically, the pneumococcal vaccine
reduces influenza-related pneumonia and hospitalization. In this
study, pneumococcal vaccine coverage was quite low (9.7%), and
more than 90% of recipients received the PPV23. Unlike protein-
conjugated vaccines, polysaccharide vaccines may not induce
mucosal immunity and cannot suppress nasopharyngeal coloni-
zation of pneumococci (18). A meta-analysis showed that poly-
saccharide vaccines were consistently ineffective in preventing
pneumococcal pneumonia, all-cause pneumonia, and related
deaths (19). Nevertheless, previous studies have shown additive or
synergistic effects between influenza and pneumococcal vaccines
in preventing pneumonia and influenza-related admission (20–
22). In the ROK, with increasing PPV23 vaccination rates in el-
derly individuals (aged 65 years), the effectiveness of PPV23
must be reassessed; in this study, 26 (37.1%) among 70 ILI pa-T
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tients with pneumonia were actually infected by Pneumococcus,
but only 4 of them received pneumococcal vaccination. In patients
aged 19 to 64 years, pneumonia, though statistically insignificant,
was rather common among pneumococcal vaccine recipients.
This unexpected finding was related to underlyingmedical condi-
tions; diabetes (9.1% versus 4.3%, P  0.10), malignancy (9.1%
versus 4.3%, P  0.10), chronic heart diseases (10.9% versus
1.8%, P  0.01), and chronic lung diseases (10.9% versus 0.8%,
P 0.01) were more common among pneumococcal vaccine re-
cipients than among unvaccinated patients. Considering the high
disease burden of nonbacteremic pneumococcal pneumonia
exclusively in elderly individuals and adults with chronic med-
ical conditions (6), the 13-valent protein-conjugated vaccine
(PCV13) may be beneficial. In addition to vaccine effective-
ness, the cost-effectiveness of each vaccine (PPV23 versus
PCV13) is also important in establishing a national immuniza-
tion strategy.
In summary, rather than the PPV23, the influenza vaccinemay
reduce postinfluenza pneumonia and hospitalization. Besides the
protective effect against influenza itself, the influenza vaccinemay
prevent complications and reduce severity in elderly adults and
those with comorbidities.
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